guest ::
| Home > Articles > Published articles > The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and its contributions to understanding Alzheimer's disease in Down syndrome : |
| Home > Articles > Published articles > The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and its contributions to understanding Alzheimer's disease in Down syndrome : |
(Institut de Recerca Sant Pau) (Fundació Catalana Síndrome de Down) (Institut de Recerca Sant Pau) (CITA-alzheimer foundation. Paseo Mikeletegi) (Institut de Recerca Sant Pau) (Institut de Recerca Sant Pau) (Institut de Recerca Sant Pau) (Institut de Recerca Sant Pau) (Institut de Recerca Sant Pau) (Institut de Recerca Sant Pau) (Institut de Recerca Sant Pau) (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) (Institut de Recerca Sant Pau) (Institut de Recerca Sant Pau) (Institut de Recerca Sant Pau) (Institut de Recerca Sant Pau) (Institut de Recerca Sant Pau) (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) (Institut de Recerca Sant Pau) (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) (Institut de Recerca Sant Pau) (Institut de Recerca Sant Pau) (Institut de Recerca Sant Pau) (Institut de Recerca Sant Pau) (Institut de Recerca Sant Pau) (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) (Hospital del Mar (Barcelona, Catalunya)) (Hospital Clínic i Provincial de Barcelona) (Hospital Clínic i Provincial de Barcelona) (Institut de Recerca Sant Pau) (Institut de Recerca Sant Pau) (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) (Institut de Recerca Sant Pau) (Institut de Recerca Sant Pau) (Institut de Recerca Sant Pau) (Institut de Recerca Sant Pau) (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) (Altoida Inc.)| Date: | 2025 |
| Abstract: | Down syndrome (DS) is a genetic form of Alzheimer's disease (AD) that offers crucial insights into AD pathogenesis. The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) is a population-based multimodal biomarker cohort studying AD's natural history and clinical trials in DS. DABNI included 1135 participants (mean age 42. 82, 46. 3% female). At baseline, 673 participants were cognitively stable, 113 had prodromal AD, 239 had AD dementia, and 110 were uncertain due to non-AD conditions. Over 10 years, > 10000 clinical visits were conducted; follow-up showed that progression to symptomatic AD before age 40 was rare, but rates increased after age 50 (> 50% within 5 years). Neuropsychological and biomarker assessments demonstrated excellent diagnostic performance and a predictable sequence of changes, similar to autosomal dominant AD. DABNI participates in AD clinical trials and produced approximately 100 publications. The 10-year DABNI study provided critical insights into DS-associated AD (DSAD) and serves as a key platform for DS clinical trials. Highlights: Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) is a population-based multimodal cohort studying Alzheimer's disease in Down syndrome. Over 10 years, 1135 participants contributed to more than 10000 clinical visits and extensive biomarker studies. DABNI findings have transformed the understanding of Alzheimer's disease in Down syndrome, reinforcing its classification as a genetic form of the disease. The cohort integrates clinical care and research, enhancing early detection and patient management. DABNI supports clinical trials and has produced over 100 publications advancing Down syndrome-related Alzheimer's research. |
| Grants: | Instituto de Salud Carlos III PI23/01767 Instituto de Salud Carlos III PI20/01330 Instituto de Salud Carlos III PI20/00836 Instituto de Salud Carlos III PI21/00791 Instituto de Salud Carlos III PI18/00435 Instituto de Salud Carlos III PI23/01786 Instituto de Salud Carlos III PI22/00611 Instituto de Salud Carlos III PI20/01473 Instituto de Salud Carlos III PI18/00335 Instituto de Salud Carlos III PI22/00307 |
| Rights: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.  |
| Language: | Anglès |
| Document: | Article de revisió ; recerca ; Versió publicada |
| Subject: | Alzheimer's disease ; DABNI ; Down syndrome ; Autosomal dominant Alzheimer's disease ; Biomarkers ; Clinical trials ; Cognition ; Health |
| Published in: | Alzheimer's & dementia, Vol. 21, Num. 6 (June 2025) , art. e70259, ISSN 1552-5279 |
